NKG2D-mediated tumor recognition and cancer immunotherapy

Takashi Morisaki, Hiroto Tanaka, Akifumi Kiyota, Norihiro Koya, Hideya Onishi, Akio Yamasaki, Hiroyuki Suzuki, Masafumi Nakamura, Mitsuo Katano

Research output: Contribution to journalArticle

Abstract

The activating receptor natural killer group 2, member D (NKG2D) and its ligands play an important role in the NK, gamma/delta T cell, and CD8 + T cell-mediated immune response to tumors. We examined the ratio and intensity of NKG2D expression before and after stimulation with IL-2 and OKT3 in ex vivo expanded lymphocytes from 29 patients who had received adoptive immunotherapy. We demonstrated that NKG2D expression rate and intensity of lymphocytes significantly increased after stimulation, and that the magnitude of NKG2D expression by activated lymphocytes was significantly correlated with prognosis. Thus, the magnitude of NKG2D expression by activated lymphocytes may correlate with the quality of clinical-grade cytotoxic T lymphocytes.

Original languageEnglish
Pages (from-to)40-45
Number of pages6
JournalBiotherapy
Volume24
Issue number1
Publication statusPublished - Jan 1 2010

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Morisaki, T., Tanaka, H., Kiyota, A., Koya, N., Onishi, H., Yamasaki, A., ... Katano, M. (2010). NKG2D-mediated tumor recognition and cancer immunotherapy. Biotherapy, 24(1), 40-45.